PPARγ activator could reduce AF susceptibility by promoting atrial cell survival [28] and inhibit cardiac fibrosis caused by several risk factors of AF, such as diabetes, hypertension, myocardial infarction, and heart failure [29]. Here, PPARG is linked to atrial fibrillation.